Loading clinical trials...
Loading clinical trials...
This study will test whether addition of imiquimod to standard antimony therapy provides a significant benefit in subjects with newly diagnosed cutaneous leishmaniasis. Based on our previous results, ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Drugs for Neglected Diseases
NCT06798402 · Cutaneous Leishmaniasis
NCT04268524 · Old World Cutaneous Leishmaniasis
NCT06692985 · Cutaneous Leishmaniasis
NCT03829917 · Cutaneous Leishmaniasis, American
NCT01300975 · Leishmaniasis, Cutaneous Leishmaniasis
UPCH
Cusco
IMT Alexander Von Humboldt
Lima
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions